These insights have resulted in a series of clinical trials that have evaluated the therapeutic potential of combining EGFR and MET TKIs in EGFR-mutated NSCLC patients who progressed on osimertinib treatment due to acquired MET alterations. Here, MET is linked to non-small cell lung carcinoma.